Income statement
USD
Annual
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | 229M | 188M | 150M | 120M | 114M |
| Gross Profit | 98M | 86M | 74M | 60M | 67M |
| Operating Income | 3M | -4M | -23M | -77M | -94M |
| EBITDA | 11M | 2M | -22M | -78M | -61M |
| Net Income | 8M | 1M | -19M | -80M | -63M |
| EPS (Diluted) | — | — | — | — | — |
Healthcare
Live Price
Offline$5.21
+0.00% today
1Y Change
+88.41%
Window
Jun 23, 2025 → May 29, 2026
Coverage: 236 bars · Jun 23, 2025 → May 29, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Talkspace, Inc. (TALK) is a Healthcare stock with a market cap of $870.00M and listed on NASDAQ. The stock last traded around $5.21 and up 88.4% across the available one-year price window (Jun 23, 2025 → May 29, 2026). Baseline metrics include revenue growth of +22.0%, EPS growth of +585.3%, a dividend yield of 0.0%. What stands out right now is revenue +22.0%, EPS +585.3%, free cash flow -133.7% with operating margin 1.4% and ROIC 2.5%. Valuation already assumes a fairly strong business story at P/E 112.2 and price/sales 3.8. Overall, the current profile looks closer to a higher-growth but lower-margin setup than a generic broad-market placeholder. Stock Foundry combines TALK price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Benchmark Comparison
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
TALK
—
Normalized return
SPY
—
S&P 500
Excess Return
—
Relative to SPY
TALK Max Drawdown
-20.91%
Trailing 1Y
SPY Max Drawdown
—
Trailing 1Y
Uses the longest available daily history for TALK and SPY.
Financial profile
Profitability, balance sheet stamina, and cash efficiency drawn from the latest filings.
FY Revenue
$113.7M
-4.9% YoY
FY Net Income
-$62.7M
+21.2% YoY
Free Cash Flow
-$66.4M
-8.1% YoY
Revenue Growth
+22.0%
EPS Growth
+585.3%
Gross Margin
43.0%
Net Margin
3.4%
Income statement
USD
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | 229M | 188M | 150M | 120M | 114M |
| Gross Profit | 98M | 86M | 74M | 60M | 67M |
| Operating Income | 3M | -4M | -23M | -77M | -94M |
| EBITDA | 11M | 2M | -22M | -78M | -61M |
| Net Income | 8M | 1M | -19M | -80M | -63M |
| EPS (Diluted) | — | — | — | — | — |
Balance sheet
USD
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Cash & Equivalents | 37M | 77M | 124M | 139M | 198M |
| Total Assets | 135M | 139M | 142M | 156M | 224M |
| Total Liabilities | 18M | 21M | 24M | 29M | 31M |
| Shareholder Equity | 117M | 117M | 119M | 128M | 192M |
| Total Debt | 0 | 0 | 0 | 500K | 0 |
| Net Debt | -37M | -77M | -124M | -138M | -198M |
Cash flow positioning
Latest Full Year
Operating Cash Flow
66M
-7.6% YoY
Capital Expenditures
663K
-89.4% YoY
Free Cash Flow
66M
-8.1% YoY
Key ratios
Gross Margin
43.0%
Operating Margin
1.4%
Net Margin
3.4%
ROE
6.9%
Debt / Equity
0.00x
Next Step
Use the numbers to decide whether this is a growth candidate, a quality compounder, or just an interesting outlier.